Giverny Capital Inc. Increases Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Giverny Capital Inc. increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 234,287 shares of the company's stock after buying an additional 7,215 shares during the period. Medpace accounts for approximately 2.8% of Giverny Capital Inc.'s investment portfolio, making the stock its 13th biggest holding. Giverny Capital Inc. owned about 0.75% of Medpace worth $77,837,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. R Squared Ltd bought a new position in shares of Medpace in the 4th quarter worth $30,000. SBI Securities Co. Ltd. bought a new stake in shares of Medpace in the 4th quarter worth $31,000. Jones Financial Companies Lllp lifted its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC boosted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a report on Monday. Truist Financial dropped their price target on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Ten research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $357.50.

Medpace Price Performance

Medpace stock traded down $0.22 during trading hours on Friday, reaching $296.28. The company had a trading volume of 698,291 shares, compared to its average volume of 325,409. The firm has a market cap of $8.96 billion, a price-to-earnings ratio of 23.46, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 12-month low of $272.00 and a 12-month high of $459.77. The company has a 50-day moving average price of $319.15 and a 200 day moving average price of $333.57.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.